Table 3.
Quartile analysis of vedolizumab serum trough concentrations and variable outcomes at week 48, n (%)
|
Quartile at week 0
|
Vedolizumab trough concentrations
(µg/mL) |
Clinical remission
|
CRP remission
|
Fecal calprotectin remission
|
Endoscopic improvement
|
Histologic remission
|
Histo-endoscopic remission (%)
|
| 1 | 5.19-10.75 | 11 (73.3) | 8 (80.0) | 8 (80.0) | 8 (61.5) | 7 (58.3) | 6 (50.0) |
| 2 | 10.75-15.60 | 14 (87.5) | 12 (85.7) | 13 (92.9) | 10 (66.7) | 10 (66.7) | 7 (46.7) |
| 3 | 15.60-20.85 | 14 (87.5) | 9 (69.2) | 12 (100) | 12 (80.0) | 9 (60.0) | 7 (46.7) |
| 4 | 20.85-41.50 | 12 (80.0) | 10 (83.3) | 10 (90.9) | 9 (64.3) | 6 (46.2) | 5 (38.5) |
| Week 48 | |||||||
| 1 | 3.33-11.30 | 9 (60.0) | 5 (62.5) | 4 (57.1) | 4 (33.3) | 5 (45.5) | 3 (27.3) |
| 2 | 11.30-15.40 | 16 (94.1) | 12 (75.0) | 15 (100.0) | 14 (82.4) | 10 (62.5) | 7 (43.8) |
| 3 | 15.40-21.70 | 13 (86.7) | 10 (90.9) | 12 (100) | 12 (80.0) | 9 (60.0) | 8 (53.3) |
| 4 | 21.70-38.40 | 13 (86.7) | 12 (85.7) | 12 (92.3) | 9 (69.2) | 8 (61.5) | 7 (53.9) |